Evidence map›Paper›PMID 24793791›Full record

ArticleOncogene2015

Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer.

Z Ren, J L Aerts, J J Pen, C Heirman, K Breckpot, J De Grève

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Z Ren1] Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium [2] Department of General Surgery, The first People's Hospital of Shanghai, Shanghai Jiaotong University, Shanghai, China [3] Department of Medical Oncology, Oncologisch Centrum of the Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
J L AertsDepartment of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.
J J Pen1] Department of Medical Oncology, Oncologisch Centrum of the Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium [2] Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.
C HeirmanDepartment of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.
K BreckpotDepartment of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.
J De Grève1] Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium [2] Department of Medical Oncology, Oncologisch Centrum of the Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Vrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The signal transducer and activator of transcription 3 (STAT3) can be activated by the tyrosine kinase domain of the chimeric protein nucleophosmin/anaplastic lymphoma kinase (NPM/ALK), and has a pivotal role in mediating NPM/ALK-related malignant cell transformation. Although the role of STAT3 and wild-type NPM in oncogenesis has been extensively investigated, the relationship between both molecules in cancer remains poorly understood. In the present study, we first demonstrate that STAT3 phosphorylation at tyrosine 705 is accompanied by a concomitant increase in the expression level of NPM. Nuclear co-translocation of phosphorylated STAT3 with NPM can be triggered by interferon-alpha (IFN-α) stimulation of Jurkat cells and phosphorylated STAT3 co-localizes with NPM in cancer cells showing constitutive STAT3 activation. We further demonstrate that STAT3 phosphorylation can transcriptionally mediate NPM upregulation in IFN-α-stimulated Jurkat cells and is responsible for maintaining its expression in cancer cells showing constitutive STAT3 activation. Inhibition of STAT3 phosphorylation or knockdown of NPM expression abrogates their simultaneous transnuclear movements. Finally, we found evidence for a physical interaction between NPM and STAT3 in conditions of STAT3 activation. In conclusion, NPM is a downstream effector of the STAT3 signaling, and can facilitate the nuclear entry of phosphorylated STAT3. These observations might open novel opportunities for targeting the STAT3 pathway in cancer.

Indexed as

Transcription, GeneticCell Line, TumorEnhancer Elements, GeneticGene Expression RegulationGene Expression Regulation, NeoplasticHumansInterferon-alphaNeoplasmsNuclear ProteinsNucleophosminPhosphorylationProtein TransportSignal TransductionSTAT3 Transcription FactorInterferon-alphaNPM1 protein, humanNuclear ProteinsNucleophosminSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID24793791
OpenAlexW1990105086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.